STOCK TITAN

Hologic Inc Stock Price, News & Analysis

HOLX Nasdaq

Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.

Hologic Inc (HOLX) delivers innovative healthcare solutions through diagnostic imaging systems and surgical technologies focused on women’s health. This dedicated news hub provides investors and industry professionals with essential updates directly from the company and verified sources.

Access timely Hologic press releases, earnings reports, and strategic announcements in one centralized location. Track developments across key business segments including diagnostic systems, breast health technologies, and minimally invasive surgical solutions. Our curated feed ensures you never miss regulatory filings, product approvals, or partnership announcements impacting this medical technology leader.

This resource serves as your primary source for monitoring Hologic’s advancements in healthcare diagnostics and operational milestones. Content is rigorously verified to maintain factual accuracy while avoiding speculative analysis. Bookmark this page for efficient tracking of HOLX’s progress in developing technologies that enhance clinical decision-making worldwide.

Rhea-AI Summary

Hologic (Nasdaq: HOLX) has completed its acquisition of Endomagnetics (Endomag), a UK-based developer of breast cancer surgery technologies, for approximately $310 million. This acquisition adds Endomag's wireless breast surgery localization and lymphatic tracing solutions to Hologic's breast surgery portfolio, including the Magseed® marker, Magtrace® lymphatic tracer, and Sentimag® platform.

The integration aims to provide breast surgeons and radiologists with an expanded range of options and enhanced user experience. Hologic's President of Breast and Skeletal Health Solutions, Erik Anderson, expressed enthusiasm about increasing access to Endomag's innovative technologies and improving outcomes for patients. Endomag's CEO, Eric Mayes, shared optimism about the opportunities for their team and the potential to impact more women globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
-
Rhea-AI Summary

A recent survey by Hologic reveals a significant gap in health screenings among American women. Despite 90% of women acknowledging the importance of regular screenings, 72 million have skipped or delayed essential tests, such as those for breast, cervical, and colorectal cancers. The Hologic Global Women's Health Index, conducted by Gallup, surveyed 4,001 women and found key barriers including lack of awareness, anxiety, and time constraints. The study highlights the need for increased awareness and education to encourage timely screenings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
Rhea-AI Summary

Hologic (Nasdaq: HOLX) announced that it will release its financial results for the third quarter of fiscal 2024 on July 29, 2024, after the market closes.

Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. To participate, dial (888) 394-8218 in the U.S. and Canada, or +1 (773) 305-6853 internationally, using access code 5372869. Alternatively, participants can join the webcast on Hologic's investor relations website.

A live and recorded webcast replay will be available on the website for 30 days, starting about two hours after the call concludes.

Hologic focuses on medical technologies that improve women's health and well-being through early detection and treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
Rhea-AI Summary

Hologic (Nasdaq: HOLX) has announced its participation in two upcoming investor conferences. The company will present at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on May 29th at 10 a.m. CT. Additionally, Hologic will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois on June 4th at 8:40 a.m. CT. Both presentations will be webcast live and available for 30 days on the company’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
-
Rhea-AI Summary

Hologic, Inc. (Nasdaq: HOLX) announced Q2 fiscal 2024 results, with revenue of $1,017.8M, GAAP EPS $0.72, Non-GAAP EPS $1.03, exceeding guidance. Total company organic revenue growth was 4.9% in constant currency. The company raised full-year revenue midpoint and EPS guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
Rhea-AI Summary

Hologic, Inc. (Nasdaq: HOLX) announced the acquisition of Endomagnetics for $310 million, enhancing their breast surgery portfolio with innovative technologies. The deal is expected to expand options for breast cancer procedures, increase global access to advanced solutions, and improve patient care. Endomag's revenue in 2023 was approximately $35 million. The acquisition will be slightly dilutive to Hologic's non-GAAP earnings per share in 2024, break even in 2025, and accretive thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
AI

FAQ

What is the current stock price of Hologic (HOLX)?

The current stock price of Hologic (HOLX) is $64.78 as of July 3, 2025.

What is the market cap of Hologic (HOLX)?

The market cap of Hologic (HOLX) is approximately 14.5B.
Hologic Inc

Nasdaq:HOLX

HOLX Rankings

HOLX Stock Data

14.51B
220.92M
0.85%
105.3%
1.98%
Medical Instruments & Supplies
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States
MARLBOROUGH